MX2023000695A - Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica. - Google Patents
Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica.Info
- Publication number
- MX2023000695A MX2023000695A MX2023000695A MX2023000695A MX2023000695A MX 2023000695 A MX2023000695 A MX 2023000695A MX 2023000695 A MX2023000695 A MX 2023000695A MX 2023000695 A MX2023000695 A MX 2023000695A MX 2023000695 A MX2023000695 A MX 2023000695A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- tau
- subject
- amount
- target material
- Prior art date
Links
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title abstract 5
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title abstract 5
- 208000034799 Tauopathies Diseases 0.000 title abstract 5
- 230000003942 amyloidogenic effect Effects 0.000 title abstract 5
- 238000003556 assay Methods 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 239000008280 blood Substances 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 title abstract 3
- 238000001514 detection method Methods 0.000 abstract 8
- 239000013077 target material Substances 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 5
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 abstract 4
- 230000035945 sensitivity Effects 0.000 abstract 4
- 239000000919 ceramic Substances 0.000 abstract 2
- 238000011002 quantification Methods 0.000 abstract 2
- 238000001513 hot isostatic pressing Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 238000005477 sputtering target Methods 0.000 abstract 1
- 238000007751 thermal spraying Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Abstract
Un método para detectar la tau p217+ en muestras basadas en sangre de un sujeto con alta sensibilidad, exactitud y precisión. El ensayo comprende poner en contacto una muestra con un anticuerpo de captura dirigido contra un epítopo de tau p217+ para unir el anticuerpo de captura a péptidos de tau p217+ en plasma para formar complejos anticuerpo-péptido, y poner en contacto por separado los complejos anticuerpo-péptido con un anticuerpo de detección para unir el anticuerpo de detección a los complejos anticuerpo-péptido. La cantidad de la tau p217+ se determina al detectar el anticuerpo de detección. La cantidad de la tau p217+ detectada se usa para determinar si el sujeto tiene tauopatía o está en riesgo de desarrollar tauopatía, o si el sujeto tiene enfermedad amiloidogénica o está en riesgo de desarrollar enfermedad amiloidogénica cuando la cantidad de péptidos de tau p217+ está por encima de un valor umbral predeterminado. El método tiene sensibilidad mejorada de tal manera que el valor umbral predeterminado está por encima de un límite inferior de cuantificación y/o límite inferior de detección del ensayo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062705759P | 2020-07-14 | 2020-07-14 | |
| US202163200399P | 2021-03-04 | 2021-03-04 | |
| PCT/EP2021/069595 WO2022013286A1 (en) | 2020-07-14 | 2021-07-14 | Blood-based assay for detecting tauopathy or amyloidogenic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000695A true MX2023000695A (es) | 2023-04-20 |
Family
ID=77168226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000695A MX2023000695A (es) | 2020-07-14 | 2021-07-14 | Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220018857A1 (es) |
| EP (1) | EP4182697A1 (es) |
| JP (1) | JP2023533806A (es) |
| KR (1) | KR20230037647A (es) |
| CN (1) | CN116348769A (es) |
| AU (1) | AU2021309020A1 (es) |
| BR (1) | BR112023000648A2 (es) |
| CA (1) | CA3189577A1 (es) |
| IL (1) | IL299822A (es) |
| MX (1) | MX2023000695A (es) |
| TW (1) | TW202217316A (es) |
| WO (1) | WO2022013286A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023242336A1 (en) | 2022-06-15 | 2023-12-21 | Janssen Pharmaceutica Nv | Blood-based screening of subjects for a clinical trial for treatment of tauopathy or amyloidogenic disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095846A (zh) * | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| ITMI20120814A1 (it) * | 2012-05-11 | 2013-11-12 | Diego Dolcetta | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
| WO2014011972A1 (en) * | 2012-07-13 | 2014-01-16 | Bristol-Myers Squibb Company | Tau immunoassay |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US11698378B2 (en) * | 2015-09-25 | 2023-07-11 | Children's Medical Center Corporation | Methods and compositions for tauopathy diagnosis and treatment |
| CN110248959B (zh) * | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| WO2019171258A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| WO2020223279A1 (en) * | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
-
2021
- 2021-07-14 JP JP2023502629A patent/JP2023533806A/ja active Pending
- 2021-07-14 CA CA3189577A patent/CA3189577A1/en active Pending
- 2021-07-14 BR BR112023000648A patent/BR112023000648A2/pt unknown
- 2021-07-14 AU AU2021309020A patent/AU2021309020A1/en active Pending
- 2021-07-14 IL IL299822A patent/IL299822A/en unknown
- 2021-07-14 KR KR1020237005147A patent/KR20230037647A/ko unknown
- 2021-07-14 TW TW110125805A patent/TW202217316A/zh unknown
- 2021-07-14 CN CN202180062649.4A patent/CN116348769A/zh active Pending
- 2021-07-14 US US17/305,764 patent/US20220018857A1/en not_active Abandoned
- 2021-07-14 WO PCT/EP2021/069595 patent/WO2022013286A1/en active Application Filing
- 2021-07-14 EP EP21749122.4A patent/EP4182697A1/en active Pending
- 2021-07-14 MX MX2023000695A patent/MX2023000695A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3189577A1 (en) | 2022-01-20 |
| IL299822A (en) | 2023-03-01 |
| EP4182697A1 (en) | 2023-05-24 |
| BR112023000648A2 (pt) | 2023-04-25 |
| AU2021309020A1 (en) | 2023-03-09 |
| WO2022013286A1 (en) | 2022-01-20 |
| JP2023533806A (ja) | 2023-08-04 |
| CN116348769A (zh) | 2023-06-27 |
| KR20230037647A (ko) | 2023-03-16 |
| TW202217316A (zh) | 2022-05-01 |
| US20220018857A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005003767A3 (en) | Elemental analysis of tagged biologically active materials | |
| EP2522985B1 (en) | Nondestructive testing of layered industrial products (for example coated medical tablets) using electromagnetic waves (for example in the terahertz range) reflected from the product | |
| ATE513200T1 (de) | Sensorvorrichtung für zielpartikel in einer probe | |
| MX2023000695A (es) | Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica. | |
| Taton et al. | Lateral flow immunoassay using magnetoresistive sensors | |
| WO2019060918A8 (en) | IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS | |
| WO2006004958A3 (en) | Detection or measurement of antibodies to antigenic proteins in biological tissues or samples | |
| Terzic et al. | Evaluation of a sensitive copeptin assay for clinical measurement | |
| ATE342500T1 (de) | Verfahren zur erkennung und kompensation der unterdosierung von teststreifen | |
| MX2021005902A (es) | Metodo basado en celulas para determinar una actividad de la toxina botulinica. | |
| Nordlund et al. | Progastrin-releasing peptide: stability in plasma/serum and upper reference limit | |
| Zhang et al. | Quantitative and rapid detection of microcystin-LR using time-resolved fluorescence immunochromatographic assay based on europium nanospheres | |
| Giovanella et al. | High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer | |
| US11835486B2 (en) | Bioanalysis test kit and method for analyzing such a test kit | |
| EP3454842A1 (en) | Use of anti-cd26 antibody levels as autoimmune and/or inflammatory disease biomarkers | |
| Nguyen et al. | Capillary electrophoresis-laser-induced fluorescence (CE-LIF)-based immunoassay for quantifying antibodies against cyclic citrullinated peptides | |
| WO2005050202A3 (en) | Biological materials and uses thereof | |
| SU1647350A1 (ru) | Способ определени механических свойств стали и сплавов | |
| US20230384311A1 (en) | Methods and related aspects for detecting unlabeled biomolecules | |
| Lim et al. | Enzyme-linked immunosorbent assay used to analyze predation of Nilaparvata lugens (Homoptera: Delphacidae) by Pirata subpiraticus (Araneae: Lycosidae) | |
| Holdgate et al. | Applications of Biophysics in Early Drug Discovery | |
| JPH05288672A (ja) | 被センシング物質の差動検出方法 | |
| Lankes et al. | Relative quantification of albumin and fibrinogen modifications by liquid chromatography tandem mass spectrometry in the diagnosis and monitoring of acute pancreatitis | |
| Reyes et al. | Implementación de un ELISA de competencia para estudios de farmacocinética del péptido CIGB-300 en plasma humano | |
| JP2007183230A (ja) | 磁性金属検出装置 |